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DEVELOPMENT AND EVALUATION OF FAST DISSOLVING THIN FILMS OF 
ARIPIPRAZOLE  
Abstract:  
In the current pharmaceutical research fast dissolving filmsare playing an important role. In the 
present research, five different rapidly dissolving films of Aripiprazole were prepared 
successfully by using different polymer such as hydroxypropyl methyl cellulose (HPMC-E5 
LV), polyvinyl pyrollidone by means of solvent casting method. Citric acid as saliva stimulating 
agent, mannitol as sweetening agent and menthol was used as flavoring agent. Aripiprazole, is an 
atypical antipsychotic. It is recommended and primarily used in the treatment of schizophrenia 
and bipolar disorder.  
The prepared films were evaluated for different parameters including thickness, mass uniformity, 
pH, folding endurance, drug content uniformity, cumulative percent release, in-vitro dissolution 
test and accelerated stability studies. In-vitro dissolutionstudies were performed dissolution 
guidelines for about 30 minutes. For analyzing the mechanism of drug release kinetics of the 
films, the data obtained were fitted to various kinetic equations of zero order, first order, Higuchi 
model and Korsmeyer-Peppas model. On the basis of different evaluated parameters formulation 
of batch F4 was found to be optimum formulation. The optimized formulation F4 was evaluated 
for the stability studies at 400 C, 75% RH for 45 days. From the evaluation, it was found that 
there is no significant change in appearance, pH, foldingendurance, drug content, in vitro 
disintegration and percentage drug release. 
Keywords: Fast dissolving thin films, Aripiprazole, first pass metabolism, bioavailability, In-
vitro dissolution studies, release kinetics. 
 
Introduction: 
At present scenario there are so many advanced drugdelivery system for administration of 
various drugs through various route, but the oral route is considered as the most convenient and 
the preferred route of administration because of low-cost and ease of administration increases the 
patient compliance
1
. More than 70% of drugs are available in the market in the form of oral drug 
delivery system. Dysphagia (difficulty in swallowing) is commonly found in pediatric and 
geriatric patients thus they tend to avoid taking oral solid dosage preparations like tablets and 
capsules due to fear of choking or suffocation due to physical obstruction
2
.  
Ultra thin postage stamp size (2x3 cm) fast dissolving oral thin-film is a novel approach, useful 
for such types of patients
3
. These films consist of hydrophilic polymers, which rapidly 
disintegrate or dissolve within a few seconds after coming in contact of saliva to release the drug 
without need of water or chewing. Since the mucosa ishighly enriched with blood supply, it 
provided quick absorption and instant bioavailability of drugs. It is suitable for the drugs that 
undergoes high first pass metabolism
4
.  
Aripiprazole is a phenylpiperazine is effective for the treatment of acute manic episodes of 
bipolar disorder in adults, children, and adolescents. It is insoluble in water and has a partition 
co-efficient of 4.537
5
. Aripiprazole is an effective add-on treatment for major depressive 
disorder; however, there is a greater rate of side effects such as weight gain and movement 
disorders. Due to presence of sweet taste and flavors drugs can be delivered just like a mouth 
freshener rather than a medicine. All these facts make Aripiprazole  an ideal candidate to prepare 
and evaluate as fast dissolving thin films. 
Materials and Methods: 
Materials: 
 HPMC E-5 LV and Polyvinyl pyrollidone were obtained from Amexco Pharmaceutical 
Company, Lagos, Nigeria.   Propylene glycol and Citric acid were obtained from Emzor 
Pharmaceuticals Limited, Lagos, Nigeria. Mannitol and menthol were obtained from Food and 
Pharma Nig. Limited, Lagos, Nigeria. 
Development of mouth dissolving film of Aripiprazole by solvent casting method- 
The casting solution was prepared by mixing polymer solutionwith drug, sweetener (Mannitol) 
and flavor (menthol) and saliva stimulating agent (citric acid) as shown in table 1. All excipients 
were added with continuous stirring. The resulting solution was deaerated by sonication, then 
poured into appropriate moulds and dried to obtain the films. The casted films were dried in oven 
at 60°C for three hours or until dryness. The final dosage form was cut into strips (2×2 cm) with 
a stainless steel cutter. The samples were packed in a high density polyethylene sheet, sealed and 
stored in desiccators at room temperature
8
. 
Evaluation of mouth dissolving films 
1. Thickness:  
Five Aripiprazole  films of each formulation were taken and the filmthickness was measured by 
using micrometer screw gauge (Glutfield Nigeria Limited, Nigeria) at different strategic 
locations (5 locations). Mean thickness and standard deviation were calculated
9
.  
2. Weight variation test: 
For weight variation test, 10 Aripiprazole  films of every formulation were randomly selected 
and weighed individually to determine the average weight and standard deviation was also 
calculated
10
.  
3. Folding endurance 
It is expressed as the number of folds required for developingvisible cracks or breaking any 
given film. This gives an indication of brittleness or flexibility of the film. A 2x2 cm strip was 
subjected to this test by folding the film at the same point repeatedly several times until a visible 
crack was observed
11
. 
4. Drug content:  
The Aripiprazole films were tested for content uniformity. Films of 2.25 cm
2 
were cut and placed 
in a 100 ml volumetric flask and dissolved in methanol and the volume was made up to 100 ml. 
Solution was suitably diluted. The absorbance of the solution was measured at 217 nm12. 
5. Surface pH of films: 
If the pH of the film is too acidic or alkaline, it may cause irritation. So it is important to 
determine surface pH of the film. Surface pH of the film shouldbe neutral i.e., 7 or should be 
close to 7. The Aripiprazole film to be tested was placed in a test tube and was moistened with 
1.0 ml of distilled water and kept for 30 second. The pH was noted by pH meter (Finlab Nigeria 
Limited, Nigeria) after bringing the electrode of the pH meter in contact with the surface of the 
formulation and allowing equilibrating for 1 min. The average of three determinations for each 
of the formulation was taken and standard deviation was also calculated
13
.  
6. Percentage moisture loss: 
For moisture content test, three Aripiprazole films of each formulation were taken. Initially, 
these selected films were weighed accurately and kept in desiccator containing fused anhydrous 
calcium chloride
14
. After 3 days, films were removed,weighed and percentage moisture loss was 
calculated using the formula- 
% Moisture loss=(Final weight-Initial weight)/(Initial weight) x100 
7. Tensile strength: 
Tensile strength of the Aripiprazole  films was checked by Universal Tensile Strength Testing 
Machine (LS5, Lloyd Instruments Limited, UK) equipped with a 500 N load cell. Test was 
 conducted under normal laboratory conditions. The film of 400 mm
2
 was randomly selected. The 
lower clamp was held stationary and the film was pulled apart by the upper clamp at a speed of 
50 mm/min. The force of the film at the point,when the film broke was recorded
15
. The 
experiment was performed in triplicate and average values were reported.  
The tensile strength at break valuewas calculated using formula: 
Tensile strength=  (Force at break (N))/(Initial cross section area) 
8. Disintegration time: 
This test is carried out using the disintegration apparatus. Three Aripiprazole  films from each 
formulation were taken and performed disintegration testby placing the films in the cylindrical 
glass tube of disintegration apparatus containing 6.8 pH phosphate buffer. The time at which film 
disintegrated is noted. Mean and standard deviation were calculated. Normally disintegration 
time for fast dissolving oral films is 5-30 seconds
16
.  
9. In vitro dissolution test 
The dissolution test on Aripiprazole  films was performed using the USP apparatus II (Finlab 
Nigeria, Limited, Nigeria). The dissolution test was performedusing the 500 ml of simulated 
saliva solution, which consist of pH 6.8 phosphate buffer as dissolution medium. The 
temperature of the medium was maintained at 37± 0.5◦C. Theapparatus was set at 50 rpm. A 
film sample of 4cm
2
 (2cm × 2cm) was cut and placed in the basket. 5 ml of samples were 
withdrawn at an interval of 2 minutes for 16 minutes and the same amount of the dissolution 
medium was replaced with fresh phosphate buffer at the same time in order to maintain the sink 
condition throughout the dissolution medium. The withdrawn samples were filtered using 
Whatmann filter paper. Appropriate dilutions were made to the withdrawn sample and were 
analyzed through UV spectrophotometer at a wavelength of 217 nm. The dissolutionstudy was 
performed in triplicates and the average value of percentage release was taken
17
.  
10. Accelerated stability studies: 
The stability studies on Aripiprazole  films were conducted according to ICH guidelines to 
investigate the effect of temperature, relative humidity on drug in formulation. Final optimized 
formulation of batch F4 was subjected to aggravated conditions oftemperature and relative 
humidity by wrapping it in aluminum foil and packaging it in glass container. The films were 
kept in stability chamber, at 40 ± 2
0
 C temperature and 75 ± 5% RH for 45 days.  After it, films 
were tested for thickness, weight variation, folding endurance, disintegration time, % drug 
content, and in-vitro drug release
18
. 
 
 Table 1: Composition of oral thin films containingAripiprazole  
Ingredients Code 
F1 F2 F3 F4 
Aripiprazole  120 120 120 120 
HPMC-E5 LV (mg) 25 50 75 100 
Polyvinyl pyrollidone 
(mg) 
50 - 100 - 
Citric acid (mg) 4 4 4 4 
Propylene glycol (ml) 0.25 0.2 0.25 0.2 
Mannitol (mg) 10 10 10 10 
Menthol (mg) 10 10 10 10 
Citric acid (mg) 200 200 200 200 
Purified Water (ml) 20 20 20 20 
 
 
Table 2: Evaluation of physicochemical parameters of Aripiprazole  films 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code  
Thickness 
(mm) 
Weight 
uniformity 
(mg) 
Surface pH 
% Drug 
content 
Moisture 
content loss  
(%)  
Folding 
endurance 
Tensile 
strength 
  (mPa) 
Disintegration 
time (Sec.)  
F1  0.15 ± 0.1 4  41.3 ± 0.68 6.38 ± 0.02 96.6± 0.28 8.41 ± 0.29  183 ± 1.02 3.67± 0.08 19± 0.48 
F2 
0.17 ± 0.23  43.2± 0.57 6.43 ± 0.03 96.51± 0.03 7.52 ± 0.25  187 ± 1.45 
2.84± 0.09 
21 ± 0.49 
F3 
0.19 ± 0.13  45.5 ± 0.16 6.74 ± 0.04 98.48± 0.48 6.82 ± 0.25  226 ± 2.03 
3.83± 0.11 
22 ± 0.51  
F4 
0.20 ± 0.09  47.6 ± 0.83 6.52 ± 0.03 99.89± 0.82 5.63 ± 0.73  232 ± 1.94 
4.23± 0.06 
24 ± 0.52 
  
Table 3: Statistical analysis of Aripiprazole  films 
Code Zero order First order Higuchi Plot Hixon-Crowell Korsmeyer- Peppas 
K0 R
2 
K1
 
R
2 
KH R
2 
KHC R
2 
KKP R
2 
N 
F1  5.6328 0.9765 0.1754 0.8963 24.321 0.9331 0.1883 0.8917 1.9471 0.8854 0.2361 
F2 6.7891 0.9647 0.1867 0.9158 25.413 0.9473 0.1741 0.8764 2.4628 0.8637 0.3114 
F3 7.0215 0.8971 0.1843 0.8951 23.541 0.9234 0.2265 0.9331 1.8243 0.9146 0.2941 
F4 6.9874 0.8558 0.2043 0.8862 25.338 0.9148 0.2345 0.9486 2.3781 0.8965 0.3252 
 
 
Figure 1: In-vitro dissolution profile of Aripiprazole films 
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Table 4: Stability study of Aripiprazole films of batch F4 
S. N. Parameter Initial After 45 days at 
40
0
 C, 75% RH 
1.  Thickness 0.20 ± 0.09 0.17±006 
2.  Weight variation 47.6 ± 0.83 47.1±0.25 
3.  Folding endurance 232 ± 1.94 229± 0.58 
4.  Disintegration Time 24 ± 0.52 22±0.64  
5.  % Drug content 99.89± 0.82 98.86± 0.08 
6.  Surface pH 6.52 ± 0.03 6.32± 0.11 
7.  In-vitro drug release 95.48% in 30 min 95.37% in 30 min 
 
RESULTS AND DISCUSSIONS 
In the present study, fast dissolving oral thin films of Aripiprazole  were prepared successfully 
by using different polymer such as hydroxypropyl methyl cellulose (HPMC-E5 LV), polyvinyl 
pyrollidone using solvent casting method. Total fiveformulations were prepared. Formulations 
were totally homogenous, flexible with smooth surface both sides. 
The films were evaluated for various properties including thickness, mass uniformity, pH, 
folding endurance, drug content uniformity, cumulative percent release, in-vitro dissolution test 
and accelerated stability studies. 
It was found that as the concentration of the polymer increases the flexibility of the film 
decreases. Films with very low concentration of polymer were sticky and brittle in nature. The 
films with optimum concentration of polymer were found to have good, flexible film forming 
property. 
 
The thicknesses of the films were found to be from 0.15 ± 0.1 4 mm to 0.20 ± 0.09 mm. The 
thicknesses of the films were found to increase with increase in concentration of the polymer. 
The weight variations of the samples were found to be in the range 41.3 ± 0.68 to 47.6 ± 0.83mg. It 
was observed that slight increase in the weight of films was due to increase in concentration of 
the polymer.  
The folding endurance of the film was found to be inthe range 183 ± 1.02 to 232 ± 1.94. The 
folding endurance was found to increases with increase in concentration of the polymer. 
The tensile strength of the prepared films was found to lie in between 2.84± 0.09 to 4.23± 0.06 
Kg/mm
2
.Tensile strength was found to increase with increase in concentration of polymer. The 
pH of the films was found to be in the range between 6.38 ± 0.02 to 6.74 ± 0.04. 
Drug content of the films with all polymers was found to be in the range of 96.51± 0.03 to 99.89± 
0.82%. Estimation of drug content indicated that the drug is uniformly distributed throughout the 
film for most of the films evidenced by the low values of standard deviation. 
The disintegration time of the films were found to be from 19± 0.48 to 24 ± 0.52seconds. It was 
observed that disintegration time of a film increases with increase in concentration of the 
polymer.  
It was observed that the drug release was found to decrease with increase in concentration of 
polymer. It indicates that increase in level of polymer, resultsin formation of high viscous gel 
layer caused by more intimate contact between the particles of polymers resulting in decreased 
 mobility of drug particles in swollen matrices, finally leading to decreased release rate.  
Formulation of batch F4 has shown maximum release 95.48% in 30 minutes. 
For analyzing the mechanism of drug release kinetics of the films, the data obtained were fitted to 
various kinetic equations of zero order, first order, Higuchi model and Korsmeyer-Peppas model. 
The regression coefficient was calculated. regression coefficients are summarized in table No. 4. 
The optimized formulation F4 was evaluated for the stability studies. Formulations were stored 
at 40
0
 C, 75% RH for 45 days. From the evaluation, it was found that there is no significant 
change in appearance, pH, foldingendurance, drug content, in vitro disintegration and percentage 
drug release. 
Conclusion: 
Fast dissolving oral thin films for oral cavity are an innovative and promising dosage form 
especially for use in pediatrics and geriatrics or others have difficulty of swallowing. The results 
have shown that the HPMC-E5 LV is a good film former. In combination with PG, it has shown 
promising fast drug release within 30 min.  Successful formulation of Aripiprazole mouth 
dissolving films may prevent first pass metabolism to a large possible extent. However to verify 
this fact there is need of in-vivo study using Aripiprazole films.  
On the basis of different evaluated parameters formulation of batch F4 was found to be optimum 
formulation. The preparation of films did not require the addition of any disintegrant separately, 
so this formulation seems to be an attractive alternative toconventional marketed formulations. 
Present study concludes that mouth dissolving films is a potential drug delivery system for 
Aripiprazole with a considerably good physicochemical characteristics and release profile. 
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